Allen Lefkowitz

Allen Lefkowitz is a Managing Director with Stifel’s Global Healthcare Group. He is a leader in Generic Pharmaceuticals advisory with more than 20 years of business development, finance, and operating experience in life sciences. Having served in senior positions at leading generics companies worldwide, Allen has worked on some of the largest transactions in the sector, including Sandoz’s landmark $1.5 billion acquisition of Fougera and Teva’s $3.4 billion acquisition of Sicor. Allen became part of Stifel in 2023 through the Torreya acquisition.

Before joining Torreya in 2013, Allen was Vice President of Business Development and Licensing at Sandoz USA, where he directed all generic and brand product licensing, as well as product and company acquisition activities. Previously, he spent nearly two decades at Teva in Israel and in the U.S., where he held positions in corporate and generics. He also served as Global CFO of Commercial Operations for Teva API. He began his career at Schering-Plough.

Allen received his B.S. in Economics and an MBA in Finance and International Business from New York University’s Stern School of Business. He is fluent in Hebrew.